All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
At the 44th European Society for Blood and Marrow Transplantation (EBMT) annual meeting, on 19 March 2018, during the lymphoma oral session 1 (OS1), Abstract OS1-4 was presented, by Jie Ji, from the Department of Hematology, West China Hospital of Sichuan University, China, on the effects of chidamide and cladribine-gemcitabine-busulfan (CGB) combination during ASCT in patients with relapsed/refractory (R/R) and poor-risk lymphoma.
High-dose chemotherapy (HDC), like BEAM conditioning is one of the most commonly used regimens for R/R lymphoma patients undergoing autologous stem cell transplantation (ASCT), as it presents with acceptable safety and efficacy. Nevertheless, a big percentage of patients relapse after ASCT and thus, the unmet medical needs of those patients have led to the investigation of novel drug regimens. Building on the results from their pre-clinical study, the authors further evaluated in this single arm, phase II trial, the efficacy and safety of CGB high-dose chemotherapy together with the histone deacetylase inhibitor (HDACi), chidamide (Chi; ChiCGB). The trial involved R/R or high-risk patients undergoing ASCT with either Hodgkin (HL) or non-Hodgkin lymphoma (NHL). The primary endpoints of this study included progression-free survival (PFS), overall survival (OS) and safety.
Dr Ji concluded that HDC ChiCGB is a new promising well-tolerated and efficient regimen that might be used as consolidation therapy along with ASCT in R/R or high-risk lymphoma patients. Nevertheless, further studies building upon these phase II results are needed to confirm the efficacy and safety profile of ChiCGB, especially for B-cell NHL patients with genetic abnormalities (TEL/DEL).
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox